Shanghai Rightongene Biotechnology Co., Ltd. commences an Equity Buyback Plan for CNY 20 million worth of its shares, under the authorization approved on February 28, 2024.

Shanghai Rightongene Biotechnology Co., Ltd. (SHSE:688217) commences a share repurchases on February 28, 2024, under the program mandated by the shareholders in the Extraordinary General Meeting held on February 19, 2024. As per the mandate, the company is authorized to repurchase up to CNY 20 million worth of its A shares. The shares will be repurchased at a price not more than CNY 49.00 per share.

The repurchased share will be used for employee stock ownership plan and equity incentives. The program will be for a period of 12 months from the shareholders? approval date.